Session » RA – Animal Models Poster

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0046

Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion

1:00PM-3:00PM: Abstract Number: 0047

Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 0048

Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice

1:00PM-3:00PM: Abstract Number: 0050

Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice

1:00PM-3:00PM: Abstract Number: 0052

Elucidating Androgen Effects on Focal Erosions in TNF-Induced Inflammatory Arthritis

1:00PM-3:00PM: Abstract Number: 0051

Identification of a Transcription Factor That Drives Polarization Toward Tissue-destructive Fibroblasts in Arthritis

1:00PM-3:00PM: Abstract Number: 0049

IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment

1:00PM-3:00PM: Abstract Number: 0054

MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts

1:00PM-3:00PM: Abstract Number: 0053

Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis

1:00PM-3:00PM: Abstract Number: 0055

Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice

1:00PM-3:00PM: Abstract Number: 0045

Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].